Drug Trial Radar · NCT04221035
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Nov 5, 2019
Primary completion
Nov 2026
Study completion Nov 2032
Sponsor
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.
Conditions
- High-Risk Neuroblastoma
- Patient With Insufficient Response Chemoimmunotherapy
Interventions
VincristineDrug
1.5 mg/m2 (max dose 2 mg)
CarboplatinDrug
750 mg/m2
EtoposideDrug
175 mg/m2
VindesineDrug
3 mg/m2/day (max dose 6 mg)
DacarbazineDrug
200 mg/m2/day
IfosfamideDrug
1500 mg/m2/day
DoxorubicinDrug
30 mg/m2/dose
BusulfanDrug
\< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
MelphalanDrug
140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
ThiotepaDrug
300 mg/m2/day over 2 hours
RadiotherapyRadiation
21.6 Gy 21.6 Gy + boost de 14.4 Gy
Dinutuximab BetaDrug
Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
CisplatinDrug
80 mg/m2/24h
Temozolomide 100 MGDrug
100 mg/m²/Day
IrinotecanDrug
50 mg/m²/jour de J0 à J4
CyclophosphamidDrug
Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event free survival (EFS)Time frame: Assessed at each end of randomization sequences up to one year
Locations
142 sites in 20 countries. Site status is shown where the registry gives one.
Children's Cancer Centre, Monash Children's Hospital
Clayton, Australia · Recruiting
Oncology/Haematology Department, Perth Children's Hospital
Nedlands, Australia · Suspended
Children's Cancer & Haematology Services, John Hunter Children's Hospital
New Lambton Heights, Australia · Recruiting
Australian and New Zealand Children's Hematology/oncology Group
Sydney, Australia · Active not recruiting
sydney children Hospital
Sydney, Australia · Recruiting
Cancer Centre for Children, The Children's Hospital
Westmead, Australia · Suspended
Sydney children Hospital
Sydney, Randwick, Australia · Recruiting
Medical University Graz
Graz, Austria · Recruiting
Landeskrankenhaus-Universitätsklinikum Innsbruck
Innsbruck, Austria · Recruiting
Kepler Universitatsklinikum Linz
Linz, Austria · Recruiting
Universitastsklinikum Salzburg
Salzburg, Austria · Recruiting
St Anna'S Children Hospital
Vienna, Austria · Recruiting
Hôpital Universitaire des Enfants Reine Fabiola (ULB)
Brussels, Belgium · Recruiting
Cliniques Universitaires Saint-Luc (UCL)
Brussels, Belgium · Recruiting
University Hospital Gent
Ghent, Belgium · Recruiting
University Hospitals Leuven
Leuven, Belgium · Recruiting
CHR Citadelle
Liège, Belgium · Recruiting
Klinika dětské onkologie FN Brno
Brno, Czechia · Not yet recruiting
University Hospital Motol
Prague, Prague, Czechia · Recruiting
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Department of Paediatrics and Adolescent Medicine, Rigshospitalet
Copenhagen, Denmark · Recruiting
The Hans Christian Andersen Children's Hospital, University of Southern Denmark
Odense, Denmark · Recruiting
New Children's Hospital, Helsinki University Hospital, Helsinki and Uusimaa Hospital District
Helsinki, Finland · Not yet recruiting
Kuopio University Hospital
Kuopio, Finland · Not yet recruiting
Oulu University Hospital
Oulu, Finland · Not yet recruiting
Tampere University Hospital
Tampere, Finland · Not yet recruiting
Turku University Hospital
Turku, Finland · Not yet recruiting
CHU d'AMIENS
Amiens, France · Recruiting
CHU angers
Angers, France · Recruiting
CHU-Pôle Médico-Chirurgical de l'Enfant et l'Adolescant
Besançon, France · Recruiting
CHU Bordeaux
Bordeaux, France · Recruiting
Groupe Hospitalier Pellegrin - Chu - Bordeaux
Bordeaux, France · Recruiting
CHU Brest
Brest, France · Recruiting
CHU Brest - Hôpital du Morvan
Brest, France · Recruiting
Centre François Baclesse
Caen, France · Active not recruiting
CHU de Caen
Caen, France · Recruiting
CHU Estaing
Clermont-Ferrand, France · Recruiting
Centre Georges-François Leclerc
Dijon, France · Active not recruiting
Hopital d'enfants Marechal de lattre
Dijon, France · Recruiting
Hôpital Couple-Enfant CHU de Grenoble
Grenoble, France · Recruiting
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.